Comparison of patient survival on adjuvant FOLFOX6 and XELOX chemotherapy after resection for gastric cancer
10.3969/j.issn.1000-8179.20140785
- VernacularTitle:胃癌术后FOLFOX6方案与XELOX方案辅助化疗的生存比较
- Author:
Xiaoqiu CHEN
;
Nannan LIU
- Publication Type:Journal Article
- Keywords:
gastric cancer;
adjuvant chemotherapy;
oxaliplatin;
5-fluorouracil;
capecitabine;
survival
- From:
Chinese Journal of Clinical Oncology
2014;(18):1195-1198
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the survival of resected gastric cancer patient treated with oxaliplatin, 5-fluorouracil, and leu-covorin (FOLFOX6) with those treated with oxaliplatin and capecitabine (XELOX). Methods:A total of 147 resected gastric cancer pa-tients accepted the treatment. Among them, 99 were treated with FOLFOX6 and 48 were treated with XELOX. Adverse events and sur-vival rates of the two groups were compared. Results:Incidence of leukopenia and hepatic dysfunction in the FOLFOX6 group was sig-nificantly higher than that of the XELOX group (P<0.05), whereas hand-foot syndrome in the XELOX group was significantly higher than that of the FOLFOX6 group (P=0.016). By contrast, the incidence of other adverse events, such as anemia, thrombocytopenia, nau-sea and vomiting, diarrhea, kidney dysfunction, peripheral neurovirulence, and oral mucositis, was not significantly different (P>0.05) between the two groups. After 1, 3, and 5 years, disease-free and overall survivals between the two groups were not significantly differ-ent (P>0.05). Conclusion:The effects of FOLFOX6 and XELOX adjuvant chemotherapies on long-term survival of resected gastric cancer patients were found to have no significant difference.
